Institutional Ethics Committee for Human Research

Standard Operating Procedure

Research Cell
Administrative Block
King George’s Medical University, UP,
Lucknow
King George's Medical University, UP, Lucknow
Institutional Ethics Committee for Human Research
Standard Operating Procedure (SOP)

Rev. Ver.-1/2019
Effective Date: 3/10/2019

<table>
<thead>
<tr>
<th>Prepared By</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Name</td>
<td>Prof. R. K. Garg</td>
</tr>
<tr>
<td>Designation</td>
<td>Member Secretary, IEC</td>
</tr>
<tr>
<td>Sign</td>
<td>Member Secretary, IEC</td>
</tr>
<tr>
<td>Date</td>
<td>King George's Medical University, Lucknow</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Approved By</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Name</td>
<td>Prof. S. P. S. Gaur</td>
</tr>
<tr>
<td>Designation</td>
<td>Chairperson, IEC</td>
</tr>
<tr>
<td>Sign</td>
<td>Chairperson, IEC</td>
</tr>
<tr>
<td>Date</td>
<td>King George's Medical University, Lucknow</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Authorized By</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Name</td>
<td>Prof. M. L. B. Bhatt</td>
</tr>
<tr>
<td>Designation</td>
<td>Vice Chancellor</td>
</tr>
<tr>
<td>Sign</td>
<td>Vice Chancellor</td>
</tr>
<tr>
<td>Date</td>
<td>03/7/19</td>
</tr>
</tbody>
</table>

SOP-Institutional Ethics Committee, KGMU (Rev. Ver.-1/2019)
<table>
<thead>
<tr>
<th>S. No.</th>
<th>Details</th>
<th>Page No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Objective</td>
<td>5</td>
</tr>
<tr>
<td>2.</td>
<td>Scope</td>
<td>5</td>
</tr>
<tr>
<td>3.</td>
<td>Role &amp; Functions of Institutional Ethics Committee (IEC)</td>
<td>5</td>
</tr>
<tr>
<td>4.</td>
<td>Composition of IEC</td>
<td>5-6</td>
</tr>
<tr>
<td>5.</td>
<td>Authority under which IEC is constituted:</td>
<td>6</td>
</tr>
<tr>
<td>6.</td>
<td>Membership Duration and Responsibilities</td>
<td>6-7</td>
</tr>
<tr>
<td>7.</td>
<td>Quorum Requirements</td>
<td>7</td>
</tr>
<tr>
<td>8.</td>
<td>Offices/Conduct of the Meeting</td>
<td>7</td>
</tr>
<tr>
<td>9.</td>
<td>Independent Consultants</td>
<td>7</td>
</tr>
<tr>
<td>10.</td>
<td>Application Procedure</td>
<td>8</td>
</tr>
<tr>
<td>11.</td>
<td>Documentation</td>
<td>8-9</td>
</tr>
<tr>
<td>12.</td>
<td>Waiver of Consent</td>
<td>9</td>
</tr>
<tr>
<td>13.</td>
<td>Review Procedure</td>
<td>10</td>
</tr>
<tr>
<td>14.</td>
<td>Element of Review</td>
<td>10</td>
</tr>
<tr>
<td>15.</td>
<td>Expedited Review</td>
<td>10-11</td>
</tr>
<tr>
<td>16.</td>
<td>Decisions Making</td>
<td>11</td>
</tr>
<tr>
<td>17.</td>
<td>Communicating the Decision</td>
<td>11</td>
</tr>
<tr>
<td>18.</td>
<td>Memorandum of Understanding and Indemnity Agreement for sponsored Drug/Device/Collaborative Trials</td>
<td>11-12</td>
</tr>
<tr>
<td>19.</td>
<td>Follow up Procedures</td>
<td>12</td>
</tr>
<tr>
<td>20.</td>
<td>Record Keeping and Archiving</td>
<td>12</td>
</tr>
<tr>
<td>21.</td>
<td>Site Monitoring and Post-monitoring activities</td>
<td>12-13</td>
</tr>
<tr>
<td>21.1</td>
<td>Before the visit</td>
<td>13</td>
</tr>
<tr>
<td>21.2</td>
<td>During the visit</td>
<td>13</td>
</tr>
<tr>
<td>21.3</td>
<td>After the visit</td>
<td>13</td>
</tr>
<tr>
<td>22.</td>
<td>Updating IEC Members</td>
<td>13-14</td>
</tr>
<tr>
<td>23.</td>
<td>Bibliography</td>
<td>14</td>
</tr>
</tbody>
</table>
ANNEXURE

DETAILS OF ANNEXURE

ANNEX. : 01 FORM TO BE FILLED BY THE PRINCIPAL INVESTIGATOR (PI) FOR SUBMISSION TO INSTITUTIONAL ETHICS COMMITTEE (IEC)

ANNEX. : 02 UNDERTAKING BY THE PRINCIPAL INVESTIGATOR

ANNEX. : 03 ONE PAGE CV FOR NON-KGMU INVESTIGATORS

ANNEX. : 04 FORMAT FOR COMMUNICATION TO THE PRINCIPAL INVESTIGATOR BY THE MEMBER SECRETARY, INSTITUTIONAL ETHICS COMMITTEE

ANNEX. : 05 INTIMATION OF START OF STUDY

ANNEX. : 06 PROGRESS REPORT (ANNUAL)/FINAL REPORT

ANNEX. : 07 GUIDELINES FOR PATIENT INFORMATION SHEET

ANNEX. : 08 INFORMED CONSENT FORM (HINDI)

ANNEX. : 09 INFORMED CONSENT FORM

ANNEX. : 10 CV OF MEMBERS OF THE INSTITUTIONAL ETHICS COMMITTEE

ANNEX. : 11 SECRECY UNDERTAKING CONFIDENTIALITY AGREEMENT FORM FOR IEC MEMBERS

ANNEX. : 12 AGREEMENT ON CONFIDENTIALITY

ANNEX. : 13 CONFLICT OF INTEREST FORM/DECLARATION FOR IEC MEMBERS

ANNEX. : 14 CONFLICT OF INTEREST

ANNEX. : 15 MEMORANDUM OF UNDERSTANDING

ANNEX. : 16 LIST OF MEMBERS OF CURRENT ETHICS COMMITTEE (2017-2020)

ANNEX. : 17 SITE MONITORING VISIT REPORT

ANNEX. : 18 MONITORING OF AUDIOVISUAL RECoding OF AV CONSENT PROCESS

SOP-Institutional Ethics Committee, KGMU (Rev. Ver.-1/2019)
Standard Operating Procedure (SOP)

1. Objective
The objective of this Standard Operating Procedure (SOP) is to ensure quality and consistency in review of clinical research proposals and to contribute to the effective functioning of the Institutional Ethics Committee (IEC) so that a quality and consistent ethical review mechanism for health and biomedical research is put in place for all proposals dealt by the Committee as prescribed by the Ethical guidelines for biomedical research on human subjects and to follow the current ICMR and national ethical guidelines for biomedical research on human subjects.

2. Scope
This SOP applies to the review and assessment of all protocols submitted for initial review and approval from the IEC. The specific points in the guidelines attached to the assessment form for initial review must be adequately addressed in the protocol itself and/or protocol related documents under review. Relevant comments made during discussion and deliberation about a specific protocol should be recorded in the minutes of the meeting. The decision reached by the IEC will be communicated to the PI.

3. Role & Functions of Institutional Ethics Committee (IEC)
- IEC will review and approve all research proposals involving human participants with a view to safeguard the dignity, rights, safety and well-being of research participants irrespective of the source of funding. The goals of research, however important, should never be permitted to override the health and well-being of the research subjects.
- The IEC will ensure that all the cardinal principles of research ethics viz, autonomy, beneficence, non-maleficence and justice are taken care of in planning, conduct and reporting of a proposed study.
- It will look into the aspects of informed consent process, risk benefit ratio, distribution of burden/benefit and provisions for appropriate compensations wherever required.
- It will review the proposals before start of the study as well as monitor the research throughout the study until and after completion of the study through periodic reports, final report and site visits etc.
- The committee will also ensure compliance with all regulatory requirements, applicable guidelines and laws.

4. Composition of IEC
- IEC shall be constituted in accordance with ICMR norms & GCP guidelines for a
period of 3 years.

- IECs should be multidisciplinary and multi-sectorial in composition. Independence and competence are the two hallmarks of an IEC.
- The Chairperson of the Committee will be a person of eminence from outside the Institution to maintain the independence of the Committee.
- The number of members in the committee shall be between 7 to 15 members.
- Faculty Incharge, Research Cell will be the Member Secretary of Institutional Ethics Committee and it will be an ex-officio post. The Member Secretary shall conduct the business of the Committee. Other members will be a mix of medical and non-medical scientific and non-scientific persons including general public to reflect the differed viewpoints.
- The composition may be as follows:

<table>
<thead>
<tr>
<th>Structure</th>
<th>Time Period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chairperson (From outside the University)</td>
<td>3 Years</td>
</tr>
<tr>
<td>Basic Medical Scientist of the University and Basic Medical Scientist from a reputed Institution (Member)</td>
<td>3 years</td>
</tr>
<tr>
<td>Senior Clinicians from various departments of the University (Member)</td>
<td>3 Years</td>
</tr>
<tr>
<td>Legal Expert or retired Judge (Member)</td>
<td>3 years</td>
</tr>
<tr>
<td>Social Scientist/ Representative of NGO (Member)</td>
<td>3 years</td>
</tr>
<tr>
<td>Philosopher/ Ethicist/ Theologian (Member)</td>
<td>3 years</td>
</tr>
<tr>
<td>Lay person (Member)</td>
<td>3 years</td>
</tr>
<tr>
<td>Member Secretary from the University</td>
<td>Ex-officio</td>
</tr>
</tbody>
</table>

- External members could be drawn from any public or private institute from anywhere in the country. There shall be adequate representation of age, gender, community etc. in the Committee to safeguard the interests and welfare of all sections of the society.

5. Authority under which IEC is constituted:

- The Vice Chancellor, KGMU, Lucknow shall constitute the IEC, in consultation with the Faculty Incharge, Research Cell.
- The Vice Chancellor will be appellate authority for any issues arising during the proceeding of review process.
- The committee will be normally reconstituted every 3 years

6. Membership Duration and Responsibilities

- The duration of the membership will be 3 years
• There will be no bar on the members serving for more than one term but it is desirable to have around one third fresh members.

• A member can be replaced in the event of death or long-term non-availability or for any action not commensurate with the responsibilities laid down in the guidelines deemed unfit for a member. Authority to replace the member shall be with the Vice Chancellor.

• A member can tender resignation from the committee with proper reasons to do so.

• Members should maintain absolute confidentiality of all discussions during the meeting and sign a confidentiality form at the start of their term. Each member of the committee will submit a declaration to maintain the confidentiality of the documents submitted to them during their membership period.

• Conflict of interest if any shall be declared by members of the IEC before the start of proceedings of the meeting.

7. Quorum Requirements

• A minimum of 5 members including at least three outside members is required for quorum. All decisions should be taken in meetings and not by circulation of project proposals.

• The ethics committee approving drug trials should have in the quorum at least one representative from the following groups:
  1. One basic medical scientist (preferably one pharmacologist).
  2. One clinician
  3. One legal expert or retired judge Ethical Review Procedures
  4. One social scientist/ representative of non-governmental organisation/ philosopher/ ethicist/theologian or a similar person
  5. One lay person from the community.

8. Offices/Conduct of the Meeting

• The Chairperson will conduct all meetings of the IEC. If for reasons beyond control, the Chairperson is not available, an alternate Chairperson will be elected by the members present from among themselves.

• The Member Secretary will be responsible for organizing the meetings, maintaining the records and communicating with all concerned. He/she will prepare the minutes of the meetings and get them approved by the Chairperson before communicating to the PI.

9. Independent Consultants

• IEC may call upon subject experts as consultants for review of selected research protocols.

• These experts may be specialists in ethical or legal aspects, specific diseases or methodologies, or represent specific communities, patient groups or special interest groups e.g. cancer patients, HIV/AIDS positive persons or ethnic minorities.

• They will not take part in the decision making process.
10. Application Procedure

- All proposals should be submitted in the prescribed application form, copies of which will be available with the Member Secretary.
- All relevant documents should be enclosed with application.
- The required number of copies of the proposal along with the application and documents in prescribed format duly signed by the PI and Co-investigators/Collaborators should be forwarded by the Head of the Department.
- The Member Secretary will acknowledge the receipt and indicate any lacunae. Missing information should be supplied within two weeks.
- The date of meeting will be intimated to the PI who should be available to offer clarifications if necessary.
- The decision of IEC will be communicated in writing. If revision is to be made, the revised document in required number of copies should be submitted within a stipulated period of time as specified in the communication.

11. Documentation

All research proposals should be submitted with the following documents:

- Title of the project
- Names of the PI and Co-investigators with designation.
- Name of any other Institute/Hospital/Field area where research will be conducted.
- Approval of the Head of the Department.
- Protocol of the proposed research.
- Ethical issues in the study and plans to address these issues.
- Proposal should be submitted with all relevant annexure like proforma, case report forms, questionnaires, follow-up cards, etc. to be used in the study.
- Patient information sheet and informed consent form in English/Hindi and local language(s) should be enclosed. The patient information sheet should provide adequate and complete information in understandable lay man language. It should also assure that any new information that becomes relevant during the trial and is related to their participation will be given to them. The consent form should be as per schedule Y published in Gazette of India (2005).
- For any drug/device trial, all relevant pre-clinical animal data and clinical trial data from other centers within the country/other countries, if available.
- Any regulatory clearances required. Copy of clearances if obtained. This is necessary for new drug/device not approved for marketing in India, justification for sending of biological samples outside India and use of radioactive pharmaceuticals in clinical studies.
- Source of funding and Budget along with the supporting documents.
• Indemnity issues including insurance for the compensation to the participants etc.
• An undertaking to ensure free treatment for research related injury (disability, chronic life-threatening disease and congenital anomaly or birth defect) and if required, payment of compensation over and above medical management by the investigator and/institution and sponsor(s), as the case may be.
• An undertaking to immediately report Serious Adverse Events (SAE) to IEC.
• Statement of conflicts of interest, if any.
• Plans for publication of results—positive or negative—while maintaining the privacy and confidentiality of the study participants.
• Any other information relevant to the study.
• Agreement to submit annual progress report and final report at the end of study.
• The PI should provide the details of other ongoing research projects (Title of the project, Date of starting and duration, source and amount of funding).

12. Waiver of Consent

A researcher cannot decide that her/his proposal falls in the exempted, expedited or full review category. All research proposals must be submitted to the EC. The decision on the type of review required rests with the EC and will be decided on a case-to-case basis. Researchers can approach the EC with appropriate justification for the proposal to be considered as exempt, expedited or if waiver of consent is requested.

The researcher can apply to the EC for a waiver of consent if the research involves less than minimal risk to participants and the waiver will not adversely affect the rights and welfare of the participants.

The EC may grant consent waiver in the following situations:

• research cannot practically be carried out without the waiver and the waiver is scientifically justified;
• retrospective studies, where the participants are de-identified or cannot be contacted;
• research on anonymized biological samples/data;
• certain types of public health studies/surveillance programmes/programme evaluation studies;
• research on data available in the public domain; or
• research during humanitarian emergencies and disasters, when the participant may not be in a position to give consent. Attempt should be made to obtain the participant's consent at the earliest.
13. Review Procedure

- Meetings of IEC shall be held on scheduled intervals as prescribed (once in 2 months or even earlier, for which the dates will be decided at the end of previous meeting). Additional meetings will be held as and when necessary.
- The proposals will be sent to members at least 2 weeks in advance.
- Decisions will be taken by consensus after discussions, and voting will be done if necessary.
- PI should be available during the meeting and may be invited to offer clarifications.
- Independent consultants/Experts may be invited to offer their opinion on specific research proposals.
- The decisions of the meeting shall be recorded in the minutes book and shall be confirmed during the next meeting with signature of Chairperson at each page.

14. Element of Review

- Scientific design and conduct of the study.
- Approval of scientific review committee and regulatory agencies.
- Assessment of predictable risks/harms and potential benefits.
- Procedure for selection of subjects including inclusion/exclusion, withdrawal criteria and other issues like sample size and advertisement details.
- Management of research related injuries, adverse events and compensation provisions.
- Justification for placebo in control arm, if any.
- Availability of products to the trial subjects after the study, if applicable.
- Patient information sheet and informed consent form in English/Hindi and local language.
- Protection of privacy and confidentiality of subjects.
- Involvement of the community, wherever necessary.
- Protocol and proforma of the study including the consent form.
- Plans for data analysis and reporting.
- Adherence to all regulatory requirements and applicable guidelines.
- Competence of investigators, research and supporting staff.
- Facilities and infrastructure.

15. Expedited Review

- Proposals which are recommended for minor revisions will be reviewed by a sub committee appointed by the IEC for clearance and approved by the Chairperson. The approvals will be reported in the next IEC meeting by Member Secretary.
• Expedited review may also be taken up in cases of nationally relevant proposals requiring urgent review.
• The revised form of proposals requiring major changes will be reviewed at the next ethics committee meeting.
• Rejected proposals may be reconsidered only if a very strong background is there.

16. Decisions Making
• A member shall recuse himself from the meeting during the decision procedure concerning an application where a conflict of interest arises. This shall be indicated to the chairperson prior to the review of the application and recorded in the minutes.
• Only members will make the decision. The decisions shall be taken in the absence of investigators, representatives of sponsors, consultants.
• Decision may be to approve, reject or revise the proposals. Specific suggestions for modifications and reasons for rejection should be given.
• Revised proposals may be subjected to an expedited review.
• All approved proposals will be subject to the following standard conditions. Additional conditions may be added by the IEC.
  ➢ PI should submit annual report of the ongoing project on format prescribed by the Institute, to the IEC.
  ➢ The final report of the completed study should be submitted by PI.
  ➢ The PI should highlight the changes in the protocols/brochures/informed consent form etc. being amended from the previous documents while submitting amended documents to IEC.

17. Communicating the Decision
• Decision will be communicated to Principal Investigator by the Member Secretary in writing.
• Suggestions for modifications and reasons for rejection will be communicated to the Principal Investigator.

18. Memorandum of Understanding and Indemnity Agreement for sponsored Drug/Device/ Collaborative Trials
• After the approval from IEC, the sponsor/CRO will submit the clinical trial agreement/Memorandum of Understanding and Indemnity Agreement document on Rs. 100 stamp paper separately (two copies) to the Institute which will be signed by sponsor, Principal Investigator and the Faculty In-charge, Research Cell after the approval of Hon’ble Vice Chancellor.
• As per existing policy of the Institute, there will be 25% overhead charges to the total cost of the trial/per patient cost.
• The drug trial shall be started by the PI after the agreement is signed by all the parties as well as required regulatory approvals from DCGI etc. are available for the concerned trial.

19. Follow up Procedures

• Annual report should be submitted by the PI on prescribed format along with comments.
• Final report should be submitted at the end of study on prescribed format including a copy of the report which has been sent to sponsoring agency.
• All SAEs and the interventions undertaken should be intimated immediately to IEC. The PI should submit the SAEs reported by other centers from time to time to the Member Secretary for information to IEC along with comments if any action is required in the current study.
• Protocol deviation, if any, should be informed with adequate justifications.
• Any amendment to the protocol should be submitted for approval.
• Any new information related to the study should be communicated to IEC.
• Change of investigators should be done with the approval of IEC.
• Premature termination of study should be notified with reasons along with summary of the data obtained so far.

20. Record Keeping and Archiving

• Curriculum Vitae (CV) of all members of IEC.
• Minutes of all meetings duly signed by the Chairperson.
• Copy of all correspondence with members, researchers and other regulatory bodies.
• All study related documents (study protocols with enclosed documents, progress reports, and SAEs.)
• A copy of filled CRF (Case Report Forms) shall remain with the PI.
• Final report of the approved projects.
• Copy of existing relevant national and international guidelines on research ethics and laws along with amendments.
• All documents should be archived for minimum of five years after the completion of study.

21. Site Monitoring and Post-monitoring activities

• Routine monitoring for a site may be decided at the time of approval of the project by the Full Board. This is recorded in the IEC minutes.
21.1 Before the visit

- Irrespective of the cause for conducting monitoring the following procedure will be followed:
- The IEC will identify and select one or more IEC members (henceforth referred to as monitors) to conduct monitoring of a site.
- The selected member/members will be given a letter in this regard.
- The agenda of monitoring will be decided by the identified monitors in consultation with the Member Secretary and Chairperson.
- The Member Secretary will decide the date of the monitoring in consultation with the monitors and the PI.
- The final date will be communicated to the PI and monitors.
- Monitors will carry with them Site Monitoring Visit Report Forms

21.2 During the visit

- The Monitor will follow the check list and oversee the progress of the study will ensure that the study conduct and data handling comply with the protocol, GCPs and applicable ethical and regulatory requirements.

21.3 After the visit

- The Monitor will submit the completed Site Monitoring Visit Report to the IEC within 7 working days of conducting a site monitoring visit or at the time of full board meeting (whichever is earlier).
- The report should describe the findings of the monitoring visit.
- The Member-Secretary will present the monitoring report at the next full board IEC meeting and the concerned Monitor will provide additional details/ clarifications to members, as required.
- The IEC will discuss the findings of the monitoring process and take appropriate action.
- The IEC will convey the decision to the Principal Investigator in writing within 14 working days of the meeting.
- The IEC will place the copy of the report in the protocol file.

22. Updating IEC Members

- All relevant information on ethics will be brought to the attention of the members of IEC by the Member Secretary.
• Members will be encouraged to attend national and international training programs/conferences/seminars in the field of research ethics to help in improving the quality of research protocols/ethics committee submissions and review.

23. Bibliography

• Good Clinical Practices for Clinical Research in India by Central Drugs Standard Control Organization, New Delhi, (Available at: http://www.cdso.org.in/html/GCP1.html)

• National Ethical guidelines for biomedical and health research involving human participants. Indian Council of Medical Research 2017. (Available at: http://ncdirindia.org/Ethics/Download/ICMR_Ethical_Guidelines_2017.pdf)
KING GEORGE'S MEDICAL UNIVERSITY, UP, LUCKNOW

FORM TO BE FILLED BY THE PRINCIPAL INVESTIGATOR (PI) FOR SUBMISSION TO INSTITUTIONAL ETHICS COMMITTEE (IEC)
(for attachment to each copy of the proposal)

* Ref. Code No. of IEC:
* to be filled by Office of IEC

Proposal Title:


<table>
<thead>
<tr>
<th>PI</th>
<th>Name, Designation &amp; Qualifications</th>
<th>Departmental Tel Nos. email ID</th>
<th>Signature</th>
</tr>
</thead>
<tbody>
<tr>
<td>Co-PI/Collaborators 1.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Please attach Curriculum Vitae of all Investigators (with subject specific publications limited to previous 5 years) not working at KGMU. The investigators should sign their CV.
### Sponsor Information

<table>
<thead>
<tr>
<th>1. Indian</th>
<th>a) Government ☐</th>
<th>Central ☐</th>
<th>State ☐</th>
<th>Institutional ☐</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>b) Private ☐</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. International</td>
<td>a) Government ☐</td>
<td>Private ☐</td>
<td></td>
<td>UN Agencies ☐</td>
</tr>
<tr>
<td>3. Industry</td>
<td>a) National ☐</td>
<td>Multinational ☐</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

4. Contact address of sponsor

5. Budget

<table>
<thead>
<tr>
<th>1. Type of study</th>
<th>Epidemiological ☐</th>
<th>Basic Sciences ☐</th>
<th>Behavioral ☐</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Clinical ☐</td>
<td>Single Centre ☐</td>
<td>Multicentric ☐</td>
</tr>
</tbody>
</table>

2. Status of review | New ☐ | Revised ☐ |

3. Clinical Trials

Drug/Vacancies/Device/Herbal Remedies
i. Does the study involve use of:
   - Drugs ☐
   - Devices ☐
   - Vaccines ☐
   - Indian systems of Medicine / or Alternate systems of Medicine ☐
   - Any other ☐
   - None ☐

ii. Is it approved and marketed:
   - In India ☐
   - UK & Europe ☐
   - USA ☐
   - Other countries, specify

iii. Does it involve a change in use, dosage, route of administration? Yes ☐ No ☐
    If yes, whether DCGI’s/Any other Regulatory Authority’s permission obtained? Yes ☐ No ☐
    If yes, copy of permission attached. Yes ☐ No ☐

iv. Is it an Investigational New Drug? Yes ☐ No ☐
    If yes,
    - a. Investigator’s Brochure enclosed Yes ☐ No ☐
    - b. Preclinical studies data available (if yes, provide summary) Yes ☐ No ☐
    - c. Clinical studies data available (if yes, provide summary) Yes ☐ No ☐
    - d. Clinical study is Phase I ☐ Phase II ☐ Phase III ☐ Phase IV ☐ N/A ☐
    - e. DCGI’s permission obtained Yes ☐ No ☐
    If yes, copy of letter enclosed Yes ☐ No ☐
4. Brief description of the proposal-aim(s) and objectives, justification for study, methodology describing the potential risks and benefits, outcome measures, statistical analysis and whether it is of national significance with rationale (Attach sheet with maximum 500 words)

5. Subject selection

<table>
<thead>
<tr>
<th>i. Number of subjects</th>
</tr>
</thead>
<tbody>
<tr>
<td>ii. Duration of</td>
</tr>
<tr>
<td>a) Study:</td>
</tr>
<tr>
<td>b) Subject participation</td>
</tr>
<tr>
<td>iii. Will subjects from both sexes be recruited</td>
</tr>
<tr>
<td>iv. Inclusion/exclusion criteria given</td>
</tr>
<tr>
<td>v. Type of subjects</td>
</tr>
<tr>
<td>Volunteers □</td>
</tr>
<tr>
<td>Patients □</td>
</tr>
<tr>
<td>vi. Vulnerable subjects</td>
</tr>
<tr>
<td>(Tick the appropriate boxes)</td>
</tr>
<tr>
<td>Pregnant Women □</td>
</tr>
<tr>
<td>Children □</td>
</tr>
<tr>
<td>Elderly □</td>
</tr>
<tr>
<td>Fetus □</td>
</tr>
<tr>
<td>Illiterate □</td>
</tr>
<tr>
<td>Handicapped □</td>
</tr>
<tr>
<td>Terminally ill □</td>
</tr>
<tr>
<td>Seriously ill □</td>
</tr>
<tr>
<td>Mentally Challenged □</td>
</tr>
<tr>
<td>Economically &amp; socially backward □</td>
</tr>
<tr>
<td>Any other □</td>
</tr>
<tr>
<td>vii. Special group subjects</td>
</tr>
<tr>
<td>(Tick the appropriate boxes)</td>
</tr>
<tr>
<td>Captives □</td>
</tr>
<tr>
<td>Institutionalized □</td>
</tr>
<tr>
<td>Employees □</td>
</tr>
<tr>
<td>Students □</td>
</tr>
<tr>
<td>Nurses / Dependent □</td>
</tr>
<tr>
<td>Armed Forces □</td>
</tr>
<tr>
<td>Any other □</td>
</tr>
<tr>
<td>viii. Confidential handling of data by staff</td>
</tr>
<tr>
<td>i. Study involves</td>
</tr>
<tr>
<td>Direct Identifiers □</td>
</tr>
<tr>
<td>Indirect Identifiers/Coded □</td>
</tr>
<tr>
<td>Completely Anonymised / Delinked □</td>
</tr>
<tr>
<td>vii. Confidential handling of data by staff</td>
</tr>
<tr>
<td>i. Study involves</td>
</tr>
<tr>
<td>Direct Identifiers □</td>
</tr>
<tr>
<td>Indirect Identifiers/Coded □</td>
</tr>
<tr>
<td>Completely Anonymised / Delinked □</td>
</tr>
</tbody>
</table>

6. Privacy and confidentiality

<table>
<thead>
<tr>
<th>i. Study involves</th>
</tr>
</thead>
<tbody>
<tr>
<td>Direct Identifiers □</td>
</tr>
<tr>
<td>Indirect Identifiers/Coded □</td>
</tr>
<tr>
<td>Completely Anonymised / Delinked □</td>
</tr>
</tbody>
</table>

7. Use of biological / hazardous materials

<table>
<thead>
<tr>
<th>i. Use of fetal tissue of aborts. If yes provide details</th>
</tr>
</thead>
<tbody>
<tr>
<td>ii. Use of organs or body fluids. If yes provide details</td>
</tr>
<tr>
<td>iii. Use of recombinant / gene therapy products</td>
</tr>
<tr>
<td>if yes, has Institutional Biosafety Committee approval for rDNA products been obtained?</td>
</tr>
<tr>
<td>iv. Use of pre-existing/stored/left over samples</td>
</tr>
<tr>
<td>v. Collection for banking / future research</td>
</tr>
<tr>
<td>vi. Use of ionizing radiation / radioisotopes</td>
</tr>
<tr>
<td>if yes, has Institutional Biosafety Committee approval for Radioactive Isotopes been obtained?</td>
</tr>
<tr>
<td>vii. Use of Infectious / biohazardous specimens</td>
</tr>
<tr>
<td>viii. Proposal disposal of material</td>
</tr>
<tr>
<td>ix. Will any sample collected from the patients be sent abroad?</td>
</tr>
<tr>
<td>If yes, give details and address of collaborators</td>
</tr>
</tbody>
</table>

Yes □ No □
8. Consent

<table>
<thead>
<tr>
<th>* Written</th>
<th>Oral</th>
<th>Audio-Visual</th>
</tr>
</thead>
<tbody>
<tr>
<td>i. Patient Information Sheet attached: (Tick the included elements)</td>
<td>Yes □ No □</td>
<td></td>
</tr>
<tr>
<td>Understandable language</td>
<td>□ Alternatives to participation</td>
<td>□</td>
</tr>
<tr>
<td>Statement that study involves research</td>
<td>□ Confidentiality of records</td>
<td>□</td>
</tr>
<tr>
<td>Sponsor of study</td>
<td>□ Contact information</td>
<td>□</td>
</tr>
<tr>
<td>Purpose and procedures</td>
<td>□ Statement that consent is voluntary</td>
<td>□</td>
</tr>
<tr>
<td>Risks &amp; discomforts</td>
<td>□ Right to withdraw</td>
<td>□</td>
</tr>
<tr>
<td>Benefits</td>
<td>□ Consent for future use of material biological</td>
<td>□</td>
</tr>
<tr>
<td>Compensation for participation</td>
<td>□ Benefits if any on future commercialization e.g. Genetic basis for drug development</td>
<td>□</td>
</tr>
<tr>
<td>Compensation for study related injury</td>
<td>□</td>
<td></td>
</tr>
<tr>
<td>Translation of information sheet in local language □</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ii. If healthy volunteers will be included, information sheet for them attached</td>
<td>Yes □ No □</td>
<td></td>
</tr>
<tr>
<td>iii. Consent form in English</td>
<td>□ Hindi</td>
<td>□</td>
</tr>
<tr>
<td>iv. Who will obtain consent (PI/Co-PI)</td>
<td>□ Nurse / Counsellor</td>
<td>□</td>
</tr>
<tr>
<td>Research Staff</td>
<td>□ Any other</td>
<td>□</td>
</tr>
</tbody>
</table>

* If written consent is not obtained, giver reasons:

9. Will any advertising be done for recruitment of Subjects?

(Posters, flyers, brochure, websites – if so attach a copy) Yes □ No □

10. Risks & benefits

i. Is the risk reasonable compared to the anticipated benefits to subjects / community / country? Yes □ No □

ii. Is there physical / social / psychological risk / discomfort? Yes □ No □

| if yes, Minimal or no risk | □ |
| More than minimum risk | □ |
| High risk | □ |

iii. Is there benefit a) to the subject? Yes □ No □

| Direct | □ |
| Indirect | □ |

b) to the society? Yes □ No □

11. Data monitoring

i. Is there a data & safety monitoring committee/Board (DSMB)? Yes □ No □

ii. Is there a plan for reporting of adverse events? Yes □ No □
if yes, reporting will be done to
Sponsor ☐ IEC ☐ DSMB ☐

iii. Is there a plan for interim analysis of data?
Yes ☐ No ☐

12. Is there compensation for injury?
If yes, by
Sponsor ☐ Investigator ☐
Insurance Company ☐ Any other ☐
Yes ☐ No ☐

13. Do you have conflict of interest?
(Financial / Non financial)
If yes, specify
Yes ☐ No ☐

Check list for attached documents:
Project proposal – 05 copies
Curriculum Vitae of non KGMU Investigators ☐
Brief description of proposal/summary ☐
Copy of the Protocol / Project and questionnaire (if any) ☐
Investigator’s Brochure ☐
Copy of Patient information sheet & Consent form in local language ☐
Copy of Advertisements/Information brochures ☐
DCGI/DBT/BARC clearance if obtained ☐
Copy of Insurance Policy ☐
Copy of Clinical trial agreement ☐
Copy of IEC proforma ☐
Copy of PI undertaking ☐
Copy of Case Report Form ☐

Signature of PI with stamp

Date

Signature of HOD with stamp
UNDEARTAKING BY THE PRINCIPAL INVESTIGATOR

1 NAME OF THE PROJECT

2 NAME, DESIGNATION AND DEPARTMENT OF THE PRINCIPAL INVESTIGATOR

3 OTHER MEMBERS OF THE RESEARCH TEAM

4 NAME AND ADDRESS OF ANY OTHER MEDICAL INSTITUTE, HOSPITAL OR INSTITUTION WHERE PARTS OF THE STUDY WILL BE DONE

5 NUMBER OF ONGOING PROJECTS/CLINICAL TRIALS IN WHICH YOU ARE PI.

- I confirm that I will initiate the study only after obtaining all regulatory clearances.
- I will not implement any deviation from the approved protocol without prior consent of the sponsor nature and it will be intimated to the IEC at the earliest.
- I confirm that the CO PI and other members of the study team have been informed about their obligations and are qualified to meet them
- I will personally supervise the study and ensure that requirements of obtaining informed consent and other ethical requirements under ICMR and National Regulatory Guidelines are adhered to.
- I will maintain accurate and complete record of all cases in accordance with GCP provisions and make them available for audit/inspection by IEC, Regulatory authorities, Sponsors or their authorized representatives.
- I will inform the IEC and the Sponsors of any unexpected or serious adverse event at the earliest and definitely within seven days of its occurrence.
- I will maintain confidentiality of the identity of all participating subjects and assure security and confidentiality of study data.
- I and my colleagues will comply with statutory obligations, requirements and guidelines applicable to such clinical studies.
- I will inform IEC of the date of starting the study within 2 weeks of initiation of the trial and submit annual progress reports and final report to Member Secretary, IEC within 4 weeks of the due date.

Signature of Principal Investigator

Date
### ONE PAGE CV FOR NON-KGMU INVESTIGATORS

<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Middle Initial</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Date of Birth (dd/mm/yy): Sex

Study Site Affiliation (e.g. Principal Investigator, Co-Investigator, Coordination)

<table>
<thead>
<tr>
<th>Professional Mailing Address (Include institution name)</th>
<th>Study Sited Address (Include institution name)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Telephone (office): Mobile Number:

Telephone (Residence): Email:

Academic Qualifications (Most current qualification first)

<table>
<thead>
<tr>
<th>Degree / Certificate</th>
<th>Year</th>
<th>Institution, Country</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Current and Previous Relevant Positions Including Academic Appointments (Most current position first)

<table>
<thead>
<tr>
<th>Month and Year</th>
<th>Title</th>
<th>Institution / Company, Country</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Brief Summary of Relevant Clinical Research Experience:

Signature: Date:

(Signature Required)
FORMAT FOR COMMUNICATION TO THE PRINCIPAL INVESTIGATOR
BY THE MEMBER SECRETARY, INSTITUTIONAL ETHICS COMMITTEE

Dated: ______________

To,
Prof./Dr. ____________________________

______________________________

Dear Prof./Dr.,

The Institutional Ethics Committee in its meeting held on ____________, has reviewed and discussed your application submitted vide letter no. ______________ dated __________, to conduct the clinical trial/project entitled "__________________________"
sponsored by ____________________________ Ref. Code no. ____________________________

The following documents were reviewed:

a. Trial protocol (including protocol amendments/project) dated ______ Version no (s)
   b. Investigator’s Brochure, dated ___________________, Version no. __________
   c. Patient information Sheet and Information Consent Form (including updates if any) in Hindi, English and/or vernacular language.
   d. Proposed methods for patient accrual including advertisement(s) proposed to be used for the purpose.
   e. Current CV of investigator from outside KGMU.
   f. Insurance Policy/Compensation for participation and for serious adverse events occurring during the study participation.
   g. Investigator’s Agreement with the Sponsor.
   h. Investigator’s Undertaking.
   i. Ethics Committee Proforma.
   j. DCGI approval letter/ submission letter.
   k. Case Report Form
   l. Any other/additional documents

Comments of Committee:

Decision of Committee:

Member Secretary
Institutional Ethics Committee
INTIMATION OF START OF STUDY

1. Project/Trial Reference Code Number
2. Title of the drug/multicentric trial
3. Principal Investigator (Name & Department)
4. Sponsor
5. Contract Research Organization (CRO) if any
6. Date of sanction by IEC
7. Date of start

(Signature of Principal Investigator)

Date:
PROGRESS REPORT (ANNUAL)/FINAL REPORT

1. Project/Trial Reference Code Number
2. Title of the Research Project/drug/multicentric trial
3. Principal Investigator (Name & Department)
4. Sponsor
5. Contract Research Organization (CRO) if any
6. Date of sanction by IEC
7. Date of start
8. Objectives of the study
9. Progress report as per objectives (attach separate sheet)
10. Serious Adverse Events if any with details (in summary form)
11. Protocol deviation if any with reasons/justifications
12. Report/publications/conference presentation
13. Awards/recognition

Date: ____________________  (Signature of Principal Investigator)

(Signature of Head of the Department)
KING GEORGE'S MEDICAL UNIVERSITY, UP, Lucknow

GUIDELINES FOR PATIENT INFORMATION SHEET

Potential recruits to your research/trial study must be given sufficient information to allow them to decide whether or not they want to take part. An Information Sheet should contain information under the headings given below where appropriate, and preferably in the order specified. It should be written in simple, non-technical terms and be easily understood by a lay person. Use short words, sentences and paragraphs.

1. Study Title
   Is the title self explanatory to a lay person? If not, an additional simplified title may also be included.

2. Invitation Paragraph
   You should explain that the patient is being asked to take part in a research/trial study. The following is an example:
   “You are being invited to take part in a research/trial study. Before you decide it is important for you to understand why the research/study is being done and what it will involve. Please take time to read the following information carefully and discuss it with friends, relatives and your treating physician/family doctor if you wish. Ask us if there is anything that is not clear or if you would like more information. Take time to decide whether or not you wish to take part.

3. What is the purpose of the study?
   The background and aim of the study should be given here.

4. Why have I been chosen?
   You should explain how and why the patient was chosen and how many other patients will be studied.

5. Do I have to take part?
   You should explain that taking part in the research/trial is entirely voluntary. You could use the following paragraph:
   “It is up to you to decide whether or not to take part. If you do decide to take part you will be given this information sheet to keep and be asked to sign a consent form. If you decide to take part you are still free to withdraw at any time and without giving a reason. This will not affect the standard of care you receive.”

6. What will happen to me if I take part?
   You should say how long the patient will be involved in the research/trial, how long the research/trial will last (if this is different), how often they will need to visit the hospital/lab or a clinic (if this is appropriate) and how long these visits will be. You should explain if the patient will need to visit the doctor (or clinic) more often than for the usual treatment and if travel expenses are available. What exactly will happen e.g. blood tests, x-rays, interviews etc? Whenever possible you should draw a simple flow chart or plan indicating what will happen at each visit. What are the patient’s responsibilities? Set down clearly what you expect of them in the form of simple instructions, for example asking them to come to the clinic at 9.00 am without having eaten anything/on an empty stomach/fasting. You should explain simply and briefly the research/trial methods you
intend to use – the following simple definitions may help.

**Randomized Trial:** Sometimes, because we do not know which way of treating patients is best, we need to make comparisons. People will be put into groups and then compared. The groups are selected by a computer, which has no information about the individual – i.e. by chance. Patients in each group then have a different treatment and these are compared. This way, the chances of something happening as a result of our choosing to put you in a specific group or bias is reduced. You should tell the patients what chance they have of getting the study drug/treatment: e.g. a one in four chance.

**Blind Trial:** In a blind trial you will not know which treatment group you are in. If the trial is a double blind trial, neither you nor your doctor will know in which treatment group you are (although, if your doctor needs to find out he/she can do so). This is done to ensure that the trial is carried out without a bias that may result from knowing which group you are in, which can adversely affect the results.

**Cross-over Trial:** In a cross-over trial both the groups have the different treatments in turn. There may be a break between treatments, a washout period, so that the effects of the first drug or treatment are cleared from your body before you start the new treatment.

**Placebo:** A placebo is a dummy treatment such as a pill, which looks like the real thing but is not. It contains no active drug, chemical or ingredient.

7. **What do I have to do?**
   Are there any lifestyle restrictions? You should tell the patient if there are any dietary restrictions. Can the patient drive? Drink? Take part in sport? Can the patient continue to take his/her regular medication? Should the patient refrain from giving blood? What happens if the patient becomes pregnant? Explain (if appropriate) that the patient should take the medication regularly.

8. **What is the drug or procedure that is being tested?**
   You should include a short description of the drug or device and give the stage of development. You should also state the dosage of the drug and method of administration. Patients entered into drug trials should preferably be given a card (similar to an identify card) with details of the trial they are in. They should be asked to carry it at all times.

9. **What are the alternatives for diagnosis or treatment?**
   For therapeutic research/trial the patient should be told what other treatment options are available.

10. **What are the side effects of taking part?**
    For any new drug or procedure you should explain to the patients the possible side effects. If they suffer these or any other symptoms they should report them next time you meet. You should also give them a contact name and number to phone if they become in any way concerned or in case of emergency. The known side effects should be listed in terms the patient will clearly understand (e.g. ‘damage to the heart’ rather than ‘cardiotoxicity’; ‘abnormalities of liver tests’ rather than ‘raised liver enzymes’). For any relatively new drug it should be explained that there may be unknown side effects.

11. **What are the possible disadvantages and risks of taking part?**
For studies where there could be harm to an unborn child if the patient were pregnant or became pregnant during the study, the following (or similar) should be said:

“IT is possible that if the treatment is given to a pregnant woman it will harm the unborn child. Pregnant women must not therefore take part in this study, neither should woman who plan to become pregnant during the study. Women who are at risk of pregnancy may be asked to have a pregnancy test before taking part to exclude the possibility of pregnancy. Women who could become pregnant must use an effective contraceptive during the course of this study. Any woman who finds that she has become pregnant while taking part in the study should immediately inform the investigator.

Use the pregnancy statement carefully. In certain circumstances (e.g. terminal illness) it would be inappropriate and insensitive to bring up pregnancy.

There should also be an appropriate warning and advice for men if the treatment could damage sperm which might therefore lead to a risk of foetal damage.

If future insurance status, e.g. for life insurance or private medical insurance, could be affected by taking part this should be stated (if e.g. high blood pressure is detected). If the patients have private medical insurance you should ask them to check with the company before agreeing to take part in the trial. They will need to do this to ensure that their participation will not affect their medical insurance.

You should clearly state what will happen if you detect or find a condition of which the patient was unaware. It is treatable? What are you going to do with this information? What might be uncovered (e.g. high blood pressure, HIV status)?

12. What are the possible benefits of taking part?

Where there is no intended clinical benefit to the patient from taking part in the trial this should be stated clearly.

It is important not to exaggerate the possible benefits to the patient during the course of the study, e.g. saying they will be given extra attention. This could be seen as coercive. It would be reasonable to say something similar to:

We hope that (all the treatments will help you. However, this can not be guaranteed. The information we get from this study may help us to treat future patients with (name of condition) better.

13. What if new information becomes available?

If additional information becomes available during the course of the research/trial you will need to tell the patient about this. You could use the following:

“Sometimes during the course of a research project/trial, new information becomes available about the treatment/drug that is being studied. If this happens, your research/trial doctor will tell you about it and discuss with you whether you want to continue in the study. If you decide to withdraw, your research/trial doctor will make arrangements for your care to continue. If you decide to continue in the study, you may be asked to sign an updated consent form. Also, on receiving new information your research/trial doctor might consider it to be in your best interests to withdraw you from the study. He/she will explain the reasons and arrange for your care to continue.”

14. What happens when the research/trial study stops?

If the treatment will not be available after the research/trial finishes this should be
explained to the patient. You should also explain to them what treatment will be available instead. Occasionally the company sponsoring the research/trial may stop it. If this is the case the reasons should be explained to the patient.

15. What if something goes wrong?
You should inform patients how complaints will be handled and what redress may be available. Is there a procedure in place? You will need to distinguish between complaints from patients as to their treatment by members of staff (doctors, nurses etc) and something serious happening during or following their participation in the trial, i.e. a reportable serious adverse event.

16. Will my taking part in this study be kept confidential?
You will need to obtain the patient’s permission to allow restricted access to their medical records and to the information collected about them in the course of the study. You should explain that all information collected about them will be kept strictly confidential. A suggested form of words for drug company sponsored research/trial is:

“If you consent to take part in the research/trial any of your medical records may be inspected by the company sponsoring (and/or the company organizing) the research/trial for purposes of analyzing the results. They may also be looked at by people from the company and from regulatory authorities to check that the study is being carried out correctly. Your name, however, will not be disclosed outside the hospital/clinic/laboratory”

“All information collected about you during the course of the research/trial will be kept strictly confidential. Any information which leaves the hospital/clinic/laboratory will have your name and address removed so that you cannot be recognized from it.”

17. What will happen to the results of the research/trial study?
You should be able to inpatients what will happen to the results of the research trial. You might add that they will not be identified in any report publication.

18. Who is organizing and funding the research/trial?
The answer should include the organization or company sponsoring or funding the research/trial
(e.g. Govt. agency, pharmaceutical company, NGO, academic institution).
The patient should be told whether the doctor conducting the research/trial is being paid for including and looking after the patient in the study. This means payment other than that to cover necessary expenses such as laboratory tests arranged locally by the researcher, or the costs of a research nurse.

19. Who has reviewed the study?
You may wish to mention that IEC has reviewed and approved the study (you should not however list the members of the Committee).

20. Contact for further information
You should give the patient a contact address for further information. This can be your name or that of another doctor/nurse involved in the study. (Name of the PI, Address, Telephone Numbers and Name of the Member Secretary of Ethics Committee and
address with telephone numbers)

Remember to thank your patient for taking part in the study!
The patient information sheet should be dated and given a version number.
The Patient Information Sheet should state that the patient will be given a copy of the
information sheet and the signed consent form.

21. Legally authorized representative

Legally authorized representative (LAR), under applicable law or judicial authority, can
give consent on behalf of a prospective participant who, for either legal or medical
reasons, is unable to give consent herself/himself to participate in research or to undergo a
diagnostic, therapeutic or preventive procedure as per research protocol, duly approved
by the ethics committee.

Date

Signature of PI
फिंग जार्ज चिकित्सा विश्वविद्यालय, उ0प्र0, लखनऊ
सूचित सहभागिता पत्र

अध्ययन का शीर्षक
अध्ययन का नाम
अन्वेषक का सम्पूर्ण विवरण

सहभागी का पूरा नाम
जन्म तिथि/उम्र
पता

भाग-1
अध्ययन का उद्देश्य--
अध्ययन की प्रक्रियाएं--
अध्ययन से जोखिम--
अध्ययन से लाभ--
सम्मानित जातिलाईँ--
शैलिपुर्ति--
गोपनीयता--
प्रतिभागी के अधिकार--
अध्ययन में भागीदारी के विकल्प--

भाग-2
1. मेरी पुष्टि है कि मैंने उपरोक्त परीक्षण हेतु जानकारी पत्र दिनांक---को पढ़ व समझ लिया है, तथा मुझे प्रश्न पूछने के अवसर प्रदान किये गये।

अर्थात
मुझे अध्ययन अन्वेषक ने विस्तार से सब तथ्यों को समझ दिया है तथा मुझे प्रश्न पूछने का अवसर प्रदान किया।

2. मैंने समझ लिया है कि इस अध्ययन में मेरी प्रतिभागिता स्वीकृत है, तथा यह कि मैं बिना कोई कारण बताए किसी भी समय अपनी चिकित्सीय देखभाल या कार्यकीय अधिकारों पर प्रभाव पड़े बिना
हट जाने के लिए स्वतंत्र हूं।

3. मैंने समझ लिया है कि चिकित्सीय प्रायोजन की ओर दे काम करने वाले अन्य, नैतिकता समग्रति
तथा विनियमक प्राथिकारियों का चालू अध्ययन तथा इससे सम्बन्धित हो सकने वाले किसी
अनुसंधान से सम्बन्धित मेरे स्वार्थमें अभिलेखों को देखने के लिए मेरी अनुमति की आवश्यकता नहीं
होगी, मलेही मैं इस परीक्षण से हट ही क्यों न जाऊँ। तथापि मैंने समझ लिया है कि तृतीय पक्ष

SOP-Institutional Ethics Committee, KGMU (Rev. Ver.-1/2019)
4. इस अध्ययन में प्राप्त किसी आकृति या पशुक्षिणों के प्रयोग पर पारंदोष न लगाने के लिए आप सहमत हैं जबकि ऐसे प्रयोग मात्र वैज्ञानिक प्रयोजनों के लिए ही हों।

5. उपयुक्त अध्ययन में भाग लेने के लिए आप सहमत हैं।

सहभागी के हस्ताक्षर या अग्निक नाम निधान/कानूनी रूप से स्वीकार्य प्रतिनिधि

हस्ताक्षर करने वाले का नाम ___________________ दिनांक _______

सहभागी से सम्बन्ध ___________________

मैं, अध्ययनकर्ता के सहभागी/कानूनी रूप से स्वीकार्य प्रतिनिधि को सरल, उनको समझने आने वाली भाषा में, अध्ययन में भाग लेने वाली प्रतिक्रियाएं और जोखिम एवं लागू से अवगत करार दिया है।

अध्ययन अन्वेषक के हस्ताक्षर _______________ दिनांक _______

अध्ययन अन्वेषक का नाम _______________ दिनांक _______

गवाह के हस्ताक्षर _______________ दिनांक _______

गवाह के हस्ताक्षर _______________ दिनांक _______
KING GEORGE'S MEDICAL UNIVERSITY, UP, LUCKNOW

INFORMED CONSENT FORM

Study Title

________________________________________________________

Study Number

________________________________________________________

Contact details of Principal-Investigator:

_________________________________________________________________________

Subject's Full Name

_________________________________________________________________________

Date of Birth/Age

_________________________________________________________________________

Address

_________________________________________________________________________

PART 1

1. Purpose of the study:

2. Study procedures:

3. Risk from the study:

4. Benefits from the study:

5. Complications:

6. Compensation:

7. Confidentiality:

8. Rights of the participants:

9. Alternatives to participation in the study:

PART 2

Consent

1. I confirm that I have read and understood the information sheet dated ___________ for the above study and have had the opportunity to ask questions.

   OR

   I have been explained the nature of the study by the Investigator and had the opportunity to ask questions

2. I understand that my participation in the study is voluntary and that I am free to withdraw at any time, without giving any reason and without my medical care or legal rights being affected.

3. I understand that the sponsor of the clinical trial/project, others working on the Sponsor’s behalf, the Ethics Committee and the regulatory authorities will not need my permission to look at my...
health records both in respect of the current study and any further research that may be conducted in relation to it, even if I withdraw from the trial. However, I understand that my Identity will not be revealed in any information released to third parties or published.

4. I agree not to restrict the use of any data or results that arise from this study provided such a use is only for scientific purpose(s)

5. I agree to take part in the above study

Signature (or Thumb impression) of the Subject/Legally Acceptable Representative: ____________________________
Signatory's Name: ____________________________
Date: ____________________________
Relationship with subject: ____________________________

Investigator's statement:-
I, the undersigned have explained to the parent/guardian in a language she/he understands the procedures to be followed in the study and risks and benefits.

Signature of the Investigator: ____________________________ Date: ____________________________
Name of the Investigator: ____________________________

Signature of the Witness: ____________________________ Date: ____________________________
Name of the Witness: ____________________________
# CV OF MEMBERS OF THE INSTITUTIONAL ETHICS COMMITTEE

King George's Medical University U.P., Lucknow

<table>
<thead>
<tr>
<th>First Name</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Middle Initial</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Last Name</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organizational Title</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Professional Mailing Address
(Include Institution Name)

| Telephone (Office) | | | |
| Mobile No. | | | |
| Email Address | | | |

Member's Specialty (Primary, Scientific, Non Scientific)

Role in K.G.M.U. Ethics Committee

## Academic Qualifications (Most current qualification first)

<table>
<thead>
<tr>
<th>Degree/Certificate</th>
<th>Year</th>
<th>Institution, Country</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Professional Experience:

<table>
<thead>
<tr>
<th>Month / Year</th>
<th>Title</th>
<th>Institution, Country</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Experience in Bioethics:

<table>
<thead>
<tr>
<th>S.No.</th>
<th>Course/Workshops/Conferences/Attended</th>
<th>Meeting Organized by</th>
<th>Place</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Members of the other Institutional Ethics Committee / Bioethics Societies with duration:

Signature:

Date:
KING GEORGE’S MEDICAL UNIVERSITY, UP, LUCKNOW

SECRECY UNDERTAKING CONFIDENTIALITY AGREEMENT
FORM FOR IEC MEMBERS

In recognition of the fact, that I, ____________________________

(Member’s name, and his/her affiliation) herein referred to as the “undersigned”, have been
appointed as a member of the KGMU-Institutional Ethics Committee (IEC) and have been asked
to assess research studies involving research participants in order to ensure that they are
conducted in a humane and ethical manner, adhering to the highest standards of care as per the
national, and local regulations and institutional policies and guidelines and international and
national guidelines;

Whereas, the appointment of the undersigned as a member of the IEC is based on individual
merits and not as an advocate or representative of a home province, territory or community nor as
a delegate of any organization or private interest;

Whereas, the fundamental duty of an IEC member is to independently review both scientific and
ethical aspects of research protocols involving human subjects and make a determination and the
best possible objective recommendations, based on the merits of the submissions under review;

Whereas, the IEC must meet the highest ethical standards in order to merit the trust and
confidence of the communities in the protection of the rights and well-being of research
participants;

The undersigned, as a member of the IEC, is expected to meet the same high standards of ethical
behavior to carry out its mandate.

This Agreement thus encompasses any information deemed Confidential or Proprietary provided
to the Undersigned in conjunction with the duties as a member of the IEC. Any written
information provided to the undersigned that is of a Confidential, Proprietary, or Privileged
nature shall be identified accordingly.

As such, the undersigned agrees to hold all Confidential or Proprietary trade secrets (“information”) in trust or confidence and agrees that it shall be used only for contemplated
purposes and shall not be used for any other purpose or disclosed to any third party. Written
Confidential information provided for review shall not be copied or retained. All Confidential
information (and any copies and notes thereof) shall remain the sole property of the IEC.

The Undersigned agrees not to disclose or utilize, directly or indirectly, any Confidential or
Proprietary information belonging to a third party in fulfilling this agreement. Furthermore, the
Undersigned confirms that his/her performance of this agreement is consistent with the institute’s
policies and any contractual obligations they may have to third parties.

Signature of IEC Member ____________________________ Date ________

Name of IEC Member ____________________________
KING GEORGE'S MEDICAL UNIVERSITY, UP, LUCKNOW

AGREEMENT ON CONFIDENTIALITY

(Please sign and date this Agreement, if the Undersigned agrees with the terms and conditions set forth above. The original (signed and dated Agreement) will be kept on file in the custody of the IEC. A copy will be given to you for your records.)

In the course of my activities as a member of the IEC, I may be provided with confidential information and documentation (which we will refer to as the Confidential Information; subject to applicable legislation, including the Access to "Confidential Information"). I agree to take reasonable measures to protect the Information Act, not to disclose the Confidential Information to any person; not to use the Confidential Information for any purpose outside the Committee's mandate, and in particular, in a manner which would result in a benefit to myself or any third party; and to destroy all Confidential Information (including any minutes or notes I have made as part of my duties) to the Chairperson upon termination of my functions as a Committee member.

I, ________________________________ (name of the member) have read and accept the aforementioned terms and conditions as explained in this Agreement.

__________________________________________
Signature of IEC Member

__________________________________________
Date

__________________________________________
Chairperson's Signature

__________________________________________
Date

I acknowledge that I have received a copy of this Agreement signed by the IEC Chairperson and me.

__________________________________________
Signature of IEC Member

__________________________________________
Date
CONFlict OF INTEREST FORM/ DECLARATION
FOR IEC MEMBERS

(Voluntary disclosure regarding COI by IEC member - The IEC member should determine whether he/she has a COI before reviewing research and declare all certain or potential conflicts of interest prior to engaging in any review process.)

I am aware of the policy of the IEC regarding conflict of interest and that no reviewer may participate in the review, comment or participate in decision making of any activity in which he/she has actual/potential conflict of interest except to provide information as requested by the IEC.

I declare ___________________________ (actual or potential COI) in relation to the proposal entitled "_____________________________" submitted for review to the IEC. The reason for COI is _________________________________.

I will refrain from the review process and /or discussion at the IEC meeting / and also will not take part in ongoing and periodic review and monitoring of this study.

______________________________  ______________________________
Signature of IEC Member                Date

______________________________
Name of IEC Member

______________________________  ______________________________
Chairperson’s Signature                Date
KING GEORGE'S MEDICAL UNIVERSITY, UP, LUCKNOW

CONFLICT OF INTEREST

IEC members should not participate in discussing, or decision making on research proposals applications reviewed at any level (exempt, expedited, or full-board) when they have conflicts of interest except to provide information requested by the IEC.

a) If an IEC member has a COI for review outside a meeting (e.g., the expedited procedure/amendments), he or she should notify the Research Cell and return the documents.

b) If an IEC member has a COI for a study for which he or she has been assigned as a primary reviewer, he or she will inform the Research Cell so that the review is reassigned to other members.

c) If an IEC member has a COI for review of a research study at a meeting, he or she will inform the Chairperson and leave the meeting room while discussion of the study takes place. He/she may stay in the meeting room only to answer questions about the research. This is applicable also for IEC meetings at which discussion on serious adverse events, deviations/violations, amendments/continuing review reports related to studies are discussed.

d) Recusal - IEC member who declares COI and leaves the meeting does not count towards the quorum for the vote. The member's absence under these circumstances is called a recusal, not an abstention or an absence.

_____________________________  ________________________________
Signature of IEC Member          Date

_____________________________
Name of IEC Member
MEMORANDUM OF UNDERSTANDING

This Memorandum of understanding (hereinafter called MoU) between King George's Medical University U.P., Lucknow, U.P., India through Faculty Incharge, Research Cell (herein after called KGMU UP), the Principal investigator of the Project (the Second Party (herein after called ) and the sponsoring Agency (the third Party ) (herein after called ) of the Project entered into on this (day) (month) (year).

Preamble:

Whereas KGMU UP is a Medical University, established by Govt. of Uttar Pradesh, as a centre of excellence for providing medical care, education and research of high order.

Whereas (the third Party)

Whereas KGMU UP and (the second party) are willing to jointly participate in the development of

The coordinator of the project will be (name and designation of the faculty member responsible from KGMU UP, Lucknow) (Second Party). The other coordinator of the project will be (name and designation of person responsible for third party).

Scope of MoU

This MoU will cover the joint efforts of King George's Medical University U.P., Lucknow (First Party), the Principal investigator of the Project (Second Party) and (third party) in the area of

(specify the area of work jointly to be done)
Furnish full details of the work to be done:

1.
2.
3.
4.

Responsibilities of KGMU UP
1.
2.
3.
4.

Responsibilities of Second Party
1.
2.
3.
4.

Responsibilities of Third Party
1.
2.
3.
4.

Administration:
Joint responsibilities of the project will be with KING GEORGE'S Medical University U.P., Lucknow (first Party), the Principal investigator of the Project (Second Party) and ___________________________(third party)

Financial Arrangements:
Funds for the projects will be from _____________________________
____________________ (name the funding agency) and the proportion of the funds to be released to KGMU UP will be Rs. ______________________ (specify the amount).

The following equipment/consumables/supplies will be provided to KGMU UP by _____________________________ (third Party)
(This is for MoU’s involving grant of equipment/consumables/supplies)

1.
2.
3.
4.

**Intellectual Property Rights:**
1. The R & D information generated shall be shared by both the collaborating parties.
2. Any publication shall be by mutual consent of second and third party.
3. Patents and other benefits, arising out of the project if any, shall be shared between all three parties.
4. For projects identified as having a distinct potential of generating know how leading to commercial applications NRDC (National Research Development Corporation of India) Guidelines will be followed.

**NRDC Guidelines:**
1. To bring to the notice of the Investigator, prospective user of the technology being developed.
2. To do market research about the product and bring out a comprehensive study about the market potential for attending entrepreneur.
3. For effective coordination between the laboratory generating the know how and the entrepreneur.
4. To take such other steps as may facilitate the communication of know how.
5. NRDC will retain 40% of the royalty/premia and the remaining 60% will be sent to the KGMU UP, generating the knowhow. The sharing of 60% between the KGMU UP and the project investigator team may be decided by the KGMU UP.

**Duration of MoU:**
This MoU will be in force for a period of ______________ (years) from the date of its signing.

**Amendments to the MOU:**
Amendments if any, before the expiry of this MOU shall be made in writing by the authorized representatives of KGMU UP and ____________________________ (third party) after mutual agreement.

**Resolution of Dispute:**
Any dispute or difference between the collaboration parties shall be amicably resolved by

SOP-Institutional Ethics Committee, KGMU (Rev. Ver.-1/2019)
either through mutual consultation or arbitration. The Vice Chancellor, KING GEORGE'S Medical University U.P. will be the arbitrator and the decision of the arbitrator shall be final.

Jurisdiction and Courts:
The MOU shall be governed by Laws of India and the parties agree to be subject to jurisdiction of competent courts at Lucknow i.e. High Court and Subordinate courts at Lucknow in addition to other places in India only.

Seal of the Parties:
In witness thereof Parties hereto have signed this MOU on the day, month and year mentioned herein before.

Parties:

(1) Signed and delivered for and behalf of KGMU UP (First Party)

(2) Signed and delivered for and behalf of (Second Party)

Signature
Name
Designation
Seal

Signature
Name
Designation
Seal

(3) Signed and delivered for and behalf of (Third)

Signature
Name
Designation
Seal

Note: This is to be written on Stamp of Rs. 100/-
<table>
<thead>
<tr>
<th>Structure</th>
<th>Name</th>
<th>Tenure</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chairman</strong></td>
<td>1. Prof. S.P.S. Gaur, Retd. Director, CDRI, Lucknow</td>
<td>For a max. period of 3 years</td>
</tr>
<tr>
<td><strong>Senior Clinician of the University</strong></td>
<td>2. Prof. A.A. Sonkar, Head, Department of Surgery (Gen.), KG MU, U.P., Lucknow</td>
<td>For a max. period of 3 years</td>
</tr>
<tr>
<td></td>
<td>3. Prof. Anoop Kumar Verma, Head, Department of Forensic Medicine, KG MU, U.P., Lucknow</td>
<td>For a max. period of 3 years</td>
</tr>
<tr>
<td></td>
<td>4. Prof. Rajeev Garg, Department of Respiratory Medicine, KG MU, U.P., Lucknow</td>
<td>For a max. period of 3 years</td>
</tr>
<tr>
<td><strong>Senior Clinician outside of the University</strong></td>
<td>5. Dr. Vimal Kumar Paliwal, Department of Neurology, SGPGIMS, Rai Barely Road, Lucknow</td>
<td>For a max. period of 3 years</td>
</tr>
<tr>
<td></td>
<td>6. Dr. Surajit Bhattacharya, Sr. Consultant Plastic Surgeon, Sahara Hospital, Lucknow</td>
<td>For a max. period of 3 years</td>
</tr>
<tr>
<td><strong>Basic Scientist of the University</strong></td>
<td>7. Prof. Amita Jain, Department of Microbiology, KG MU, U.P., Lucknow</td>
<td>For a max. period of 3 years</td>
</tr>
<tr>
<td></td>
<td>8. Prof. Rajendra Nath, Department of Pharmacology, KG MU, U.P., Lucknow</td>
<td>For a max. period of 3 years</td>
</tr>
<tr>
<td></td>
<td>9. Dr. Preeti Agarwal, Department of Pathology, KG MU UP, Lucknow</td>
<td>For a max. period of 3 years</td>
</tr>
<tr>
<td><strong>Chairman &amp; Legal Expert</strong></td>
<td>10. Hon’ble Justice Vishnu Sahai (Retd.)</td>
<td>For a max. period of 3 years</td>
</tr>
<tr>
<td><strong>Basic Scientist outside of the University</strong></td>
<td>11. Dr. Smriti Bhadoria, Toxicology &amp; Experimental Medicine, CSIR-Central Drug Research Institute, BS-10/1, Sector 10, Jankipuram extension, Lucknow</td>
<td>For a max. period of 3 years</td>
</tr>
<tr>
<td><strong>Lay Person</strong></td>
<td>12. Sri Ram Niwas Jain, A-2, Sindhu Nagar, Kanpur Road, Lucknow-226003</td>
<td>For a max. period of 3 years</td>
</tr>
<tr>
<td><strong>Social Scientist/Philosopher/Ethicist/Theologian</strong></td>
<td>13. Dr. Manju Agrawal, Director, Amity Institute of Behavioral &amp; Allied Sciences, Amity University Campus, Lucknow</td>
<td>For a max. period of 3 years</td>
</tr>
<tr>
<td><strong>Member-Secretary</strong></td>
<td>14. Prof. R.K. Garg, Faculty Incharge, Research Cell, KG MU UP, Lucknow</td>
<td>Ex-Officio</td>
</tr>
</tbody>
</table>
Site Monitoring Visit Report

(Please tick the box corresponding to the answer)

<table>
<thead>
<tr>
<th>IEC Project NO.</th>
<th>Date of Visit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study Title:</td>
<td></td>
</tr>
<tr>
<td>Principal Investigator and Department</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Type of Study</th>
<th>Investigator initiated</th>
<th>Pharma</th>
<th>Thesis</th>
</tr>
</thead>
</table>

☐ Government agency  Others ______________________
<table>
<thead>
<tr>
<th>Date of IEC approval:</th>
<th>Routine</th>
<th>For-cause (state reason/s)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Protocol Violations/Deviations</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SAE reporting</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Recruitment rate</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Other______________</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Last monitoring done. If any,</th>
<th>Yes</th>
<th>Date of last monitoring ................................</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Project Status</th>
<th>1. Ongoing</th>
</tr>
</thead>
<tbody>
<tr>
<td>2. Completed</td>
<td></td>
</tr>
<tr>
<td>3. Recruitment Completed</td>
<td></td>
</tr>
<tr>
<td>4. Follow-up, extension study</td>
<td></td>
</tr>
<tr>
<td>5. Suspended</td>
<td></td>
</tr>
<tr>
<td>6. Terminated</td>
<td></td>
</tr>
</tbody>
</table>

In case of the response to the above question is option 5 or 6. Kindly provide reason/s

<table>
<thead>
<tr>
<th>Recruitment Status:</th>
<th>Total patients to be recruited ____________</th>
</tr>
</thead>
<tbody>
<tr>
<td>Screened:</td>
<td></td>
</tr>
<tr>
<td>Screen failure:</td>
<td></td>
</tr>
<tr>
<td>Enrolled</td>
<td></td>
</tr>
<tr>
<td>Withdrawn:</td>
<td>Reason</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Discontinued:</td>
<td>Reason</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Completed:</td>
<td></td>
</tr>
<tr>
<td>Active:</td>
<td></td>
</tr>
<tr>
<td>Question</td>
<td>Comment</td>
</tr>
<tr>
<td>-------------------------------------------------------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>Are the present study team members as per the list approved by the IEC?</td>
<td></td>
</tr>
<tr>
<td>□ Yes □ No</td>
<td></td>
</tr>
<tr>
<td>Are site facilities appropriate?</td>
<td></td>
</tr>
<tr>
<td>□ Yes □ No</td>
<td></td>
</tr>
<tr>
<td>Is the recent version of Informed Consent Document (ICD) after IEC approval used?</td>
<td></td>
</tr>
<tr>
<td>□ Yes □ No</td>
<td></td>
</tr>
<tr>
<td>Whether appropriate vernacular consent has been taken from all patients?</td>
<td></td>
</tr>
<tr>
<td>□ Yes □ No</td>
<td></td>
</tr>
<tr>
<td>Any other findings noted about the ICDs?</td>
<td></td>
</tr>
<tr>
<td>□ Yes □ No</td>
<td></td>
</tr>
<tr>
<td>Is recent IEC approved version of protocol used?</td>
<td></td>
</tr>
<tr>
<td>□ Yes □ No</td>
<td></td>
</tr>
<tr>
<td>Have the eligibility, inclusion exclusion criteria been adhered to?</td>
<td></td>
</tr>
<tr>
<td>□ Yes □ No</td>
<td></td>
</tr>
<tr>
<td>Any adverse events found?</td>
<td></td>
</tr>
<tr>
<td>□ Yes □ No</td>
<td></td>
</tr>
<tr>
<td>Question</td>
<td>Comment</td>
</tr>
<tr>
<td>------------------------------------------------------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>Any SAEs found?</td>
<td></td>
</tr>
<tr>
<td>□ Yes □ No</td>
<td></td>
</tr>
<tr>
<td>Were the SAEs informed to IEC within timelines specified by CDSCO?</td>
<td></td>
</tr>
<tr>
<td>□ Yes □ No</td>
<td></td>
</tr>
<tr>
<td>No. of details reported:</td>
<td></td>
</tr>
<tr>
<td>□ Deaths unrelated to participation in the trial:</td>
<td></td>
</tr>
<tr>
<td>□ Deaths related to participation in the trial:</td>
<td></td>
</tr>
<tr>
<td>Any other non-death study related injury</td>
<td>□ Yes □ No □ NA</td>
</tr>
<tr>
<td>Comments (if any)</td>
<td></td>
</tr>
<tr>
<td>Compensation paid for study related injury or death</td>
<td>□ Yes □ No □ NA</td>
</tr>
<tr>
<td>Comment (if any)</td>
<td></td>
</tr>
<tr>
<td>Are there any protocol non-compliance deviations / violations?</td>
<td></td>
</tr>
<tr>
<td>□ Yes □ No</td>
<td></td>
</tr>
<tr>
<td>Have the protocol non-compliance deviations/violations been informed to IEC?</td>
<td></td>
</tr>
<tr>
<td>□ Yes □ No</td>
<td></td>
</tr>
<tr>
<td>Are all Case Record Forms up to date?</td>
<td></td>
</tr>
<tr>
<td>□ Yes □ No</td>
<td></td>
</tr>
</tbody>
</table>
**Are storage of data and investigating products locked?**

- Yes  
- No

**Comment**

**How well are the participants protected?**

- Good  
- Fair  
- Not good

**Comment**

**Any other remarks**

- Yes  
- No

**Give details**

**Duration of visit:** ________ hours  
**Starting from**  
**finish**

**Name of the study team member/s present**

**Date**

**Signature:** ____________________

**Name of IEC members and representatives who attended monitoring visit:**

**Date**

**Completed by**

**Signature:** ____________________

**Final Decision at the IEC meeting held on**

________________________________________

________________________________________

________________________________________

________________________________________

Signature of Chairperson, IEC with date
Monitoring of Audiovisual recoding of AV consent Process

1. Facility where informed consent process should be carried out – (well lit, free from noise, privacy ensured):
   - Yes _______  No _______
   - Remarks: ____________________________

2. The consent is taken in language the participant/LAR understands best and is literate in,
   - Yes _______  No _______
   - Remarks: ____________________________

3. Introduction of each person (person conducting the informed consent discussion participant / legally acceptable representative (LAR)/impartial witness) involved during informed consent process and information about necessity for audiovisual recording.
   - Yes _______  No _______
   - Remarks: ____________________________

4. Information to the participant/LAR and impartial witness (as applicable) that the process of taking the consent is being recorded for the purpose of documentation as required by the government rules.
   - Yes _______  No _______
   - Remarks: ____________________________

5. Information to the participant/LAR and impartial witness (As applicable) that the confidentiality of information and privacy of participants is assured.
   - Yes _______  No _______
   - Remarks: ____________________________

6. Information to the participant / LAR and impartial witness (as applicable) that the recording may be shown to government agencies or members from the IEC.
   - Yes _______  No _______
   - Remarks: ____________________________

7. Explanation or narration by the person conducting the informed consent discussion.

SOP-Institutional Ethics Committee, KGMU (Rev. Ver.-1/2019)
8. Question asked by the potential participant / LAR are answered satisfactorily.

- Yes ______  No ______
- Remarks: ____________________________

9. Allowing ample time and opportunity to read/understand the information in the informed consent document or discuss the same with family members.

- Yes ______  No ______
- Remarks: ____________________________

10. Reading out by the participant / LAR (or having read out by impartial witness) the statements mentioned in Informed Consent and stating whether participant agrees or not for each statement.

- Yes ______  No ______
- Remarks: ____________________________


- Yes ______  No ______
- Remarks: ____________________________

12. Clarity and completeness of AV recording

- Yes ______  No ______
- Remarks: ____________________________

13. Storage of recording in password protected laptop / desktop computer and/or hard drive and labelled CD with access allowed only to the principal investigator and designated members of the study team.

- Yes ______  No ______
- Remarks: ____________________________
<table>
<thead>
<tr>
<th>Structure</th>
<th>Name</th>
<th>Signature</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chairman</strong></td>
<td>1. Prof. S.P.S. Gaur, Retd. Director, CDRI, Lucknow</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. Prof. A.A. Sonkar, Head, Department of Surgery (Gen.), KGMU, U.P., Lucknow</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3. Prof. Anoop Kumar Verma, Head, Department of Forensic Medicine, KGMU, U.P., Lucknow</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4. Prof. Rajeev Garg, Department of Respiratory Medicine, KGMU, U.P., Lucknow</td>
<td></td>
</tr>
<tr>
<td><strong>Senior Clinician of the University</strong></td>
<td>5. Dr. Vimal Kumar Paliwal, Department of Neurology, SGPGIMS, Rai Barely Road, Lucknow</td>
<td></td>
</tr>
<tr>
<td></td>
<td>6. Dr. Surajit Bhattacharya, Sr. Consultant Plastic Surgeon, Sahara Hospital, Lucknow</td>
<td></td>
</tr>
<tr>
<td><strong>Senior Clinician outside of the University</strong></td>
<td>7. Prof. Amita Jain, Department of Microbiology, KGMU, U.P., Lucknow</td>
<td></td>
</tr>
<tr>
<td></td>
<td>8. Prof. Rajendra Nath, Department of Pharmacology, KGMU, U.P., Lucknow</td>
<td></td>
</tr>
<tr>
<td></td>
<td>9. Dr. Preeti Agarwal, Department of Pathology, KGMU UP, Lucknow</td>
<td></td>
</tr>
<tr>
<td><strong>Basic Scientist of the University</strong></td>
<td>10. Hon’ble Justice Vishnu Sahai (Retd.)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>11. Dr. Smriti Bhadoria, Toxicology &amp; Experimental Medicine, CSIR-Central Drug Research Institute, BS-10/1, Sector 10, Jankipuram extension, Lucknow</td>
<td></td>
</tr>
<tr>
<td><strong>Chairman &amp; Legal Expert</strong></td>
<td>12. Sri Ram Niwas Jain, A-2, Sindhu Nagar, Kanpur Road, Lucknow-226003</td>
<td></td>
</tr>
<tr>
<td><strong>Basic Scientist outside of the University</strong></td>
<td>13. Dr. Manju Agrawal, Director, Amity Institute of Behavioral &amp; Allied Sciences, Amity University Campus, Lucknow</td>
<td></td>
</tr>
<tr>
<td><strong>Lay Person</strong></td>
<td>14. Prof. R.K. Garg, Faculty Incharge, Research Cell, KGMU UP, Lucknow</td>
<td></td>
</tr>
</tbody>
</table>

SOP-Institutional Ethics Committee, KGMU (Rev. Ver.-1/2019)